Alicia Grande Biography and Net Worth

Alicia Grande, CPA, CMA, was appointed Vice President, Chief Financial Officer and Treasurer of Catalyst in December 2011, having joined the company as Corporate Controller and Chief Accounting Officer in 2007. Prior to that, she was Senior Director of Finance for The Hackett Group, Inc. (then known as Answerthink, Inc.), where she was responsible for all external and SEC financial reporting and served as head of the firm’s Sarbanes-Oxley Act compliance team. Ms. Grande previously was employed for more than 10 years by various public accounting firms, including Arthur Andersen, LLP. Ms. Grande earned a bachelor of science degree in business administration, with majors in accounting and finance, from Syracuse University and a master of accounting degree from Florida International University.

What is Alicia Grande's net worth?: The estimated net worth of Alicia Grande is at least $775,544.38 as of December 8th, 2023. Ms. Grande owns 50,557 shares of Catalyst Pharmaceuticals stock worth more than $775,544 as of April 18th. This net worth approximation does not reflect any other assets that Ms. Grande may own. Learn More about Alicia Grande's net worth.
How do I contact Alicia Grande?: The corporate mailing address for Ms. Grande and other Catalyst Pharmaceuticals executives is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. Catalyst Pharmaceuticals can also be reached via phone at (305) 420-3200 and via email at [email protected]. Learn More on Alicia Grande's contact information.
Has Alicia Grande been buying or selling shares of Catalyst Pharmaceuticals?: Alicia Grande has not been actively trading shares of Catalyst Pharmaceuticals within the last three months. Most recently, Alicia Grande sold 60,000 shares of the business's stock in a transaction on Monday, December 11th. The shares were sold at an average price of $13.76, for a transaction totalling $825,600.00. Following the completion of the sale, the chief financial officer now directly owns 50,557 shares of the company's stock, valued at $695,664.32. Learn More on Alicia Grande's trading history.
Who are Catalyst Pharmaceuticals' active insiders?: Catalyst Pharmaceuticals' insider roster includes Philip Coelho (Director), Alicia Grande (CFO), Alicia Grande (Vice President, Chief Financial Officer and Treasurer), Gary Ingenito (Insider), Patrick McEnany (CEO), Steve Miller (COO), and Steven Miller (COO & Chief Scientific Officer ). Learn More on Catalyst Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Catalyst Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 7 times. They sold a total of 266,151 shares worth more than $3,781,377.73. The most recent insider tranaction occured on April, 8th when Director David S Tierney sold 25,000 shares worth more than $392,000.00. Insiders at Catalyst Pharmaceuticals own 12.1% of the company. Learn More about insider trades at Catalyst Pharmaceuticals.
Information on this page was last updated on 4/8/2024.

Alicia Grande Insider Trading History at Catalyst Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/11/2023	Sell	60,000	$13.76	$825,600.00	50,557
12/8/2023	Sell	40,000	$14.28	$571,200.00	50,557
3/28/2023	Sell	58,216	$16.54	$962,892.64	50,557
3/22/2023	Sell	41,784	$16.50	$689,436.00	50,557
11/22/2022	Sell	120,000	$16.53	$1,983,600.00	27,442
11/15/2022	Sell	60,000	$15.77	$946,200.00	147,442
9/23/2022	Sell	60,000	$11.90	$714,000.00	207,442
9/16/2022	Sell	90,000	$13.50	$1,215,000.00	267,442
9/14/2022	Sell	50,000	$15.57	$778,500.00	357,442
8/29/2022	Sell	57,000	$14.20	$809,400.00	407,442
8/26/2022	Sell	11,095	$14.40	$159,768.00	464,442
8/17/2022	Sell	130,741	$13.86	$1,812,070.26	475,537
8/17/2021	Sell	100,000	$5.67	$567,000.00	507,441

Alicia Grande Buying and Selling Activity at Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Company Overview

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Today's Range

Now: $15.34

$15.33

$16.25

50 Day Range

MA: $15.38

$13.18

$17.01

2 Week Range

Now: $15.34

$11.09

$17.78

Volume

1,493,160 shs

Average Volume

1,423,779 shs

Market Capitalization

$1.81 billion

P/E Ratio

25.15

Dividend Yield

N/A

Beta

0.89

Biden’s $374B Giveaway Into This Sector

From DTI | Ad

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story